ArticleBMJ open sport & exercise medicine2026
Adverse events associated with local anaesthetic use in musculoskeletal injection therapy: a scoping review.
Article in BMJ open sport & exercise medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Musculoskeletal disorders (MSDs) are a leading cause of disability worldwide and account for a substantial proportion of healthcare utilisation. Injection therapy combining corticosteroids with local anaesthetic (LA) is widely used for MSD management, including within physiotherapy practice. Despite widespread use, uncertainty remains regarding the safety profile of LAs and the potential risk of adverse events. Objective: To map the available evidence on adverse events and associated risk factors following local anaesthetic use in the management of musculoskeletal disorders. Methods: A scoping review was conducted following Joanna Briggs Institute methodology and reported according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) guidelines. MEDLINE, CINAHL, PubMed and Cochrane were searched from database inception to 2025, alongside targeted grey literature searching. Studies reporting adverse effects of LAs administered for musculoskeletal conditions within physiotherapy scope of practice were included. Data were extracted by multiple reviewers and synthesised thematically. Results: 39 sources were included. Cytotoxicity, particularly chondrotoxicity, was the most frequently reported adverse effect, appearing in 74% of included sources. Evidence indicated reduced chondrocyte viability, mitochondrial dysfunction and apoptosis following exposure to commonly used agents such as lidocaine and bupivacaine. Systemic toxicity, allergic reactions and psychogenic responses were reported less frequently. Key risk factors included higher dose or concentration, prolonged exposure duration, continuous intra-articular infusion, patient comorbidities and accidental intravascular injection. Conclusion: Evidence on adverse effects of LA use in MSD management is heterogeneous but consistently highlights cytotoxicity as a potential concern. Further clinical research is required to quantify risk and guide safer injection practices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.